Evaluating Treatment Plans: The Role of GLP-1 Receptor Agonists

Treatment plans are primarily guided by American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. These guidelines advocate for individualized treatment approaches that prioritize glycemic control and aim to reduce cardiovascular and renal complications. The selection of antihyperglycemic therapies is based on glucose-lowering efficacy and comorbid conditions like chronic kidney disease (CKD) and cardiovascular disease.

Glucagon-like peptide-1 (GLP-1) receptor agonists are supported by substantial evidence from large cardiovascular outcome trials. These trials indicate significant reductions in major adverse cardiovascular events (MACE) and slower progression of diabetic kidney disease in patients with type 2 diabetes mellitus (T2DM). Semaglutide, a specific GLP-1 receptor agonist, has shown superior reductions in hemoglobin A1C and body weight compared to other glucose-lowering agents. Consequently, ADA and KDIGO guidelines recommend GLP-1 receptor agonists for patients with established atherosclerotic cardiovascular disease, high cardiovascular risk, or CKD, especially when additional glycemic control or weight reduction is needed.

Despite their benefits, GLP-1 receptor agonists have limitations. Common gastrointestinal side effects such as nausea, vomiting, and diarrhea can impact medication adherence and quality of life. The high cost and variable insurance coverage can also limit patient access. While these agents offer renal protection, sodium-glucose cotransporter-2 (SGLT2) inhibitors generally provide greater nephroprotective benefits, particularly in slowing CKD progression and reducing heart failure hospitalization. Therefore, treatment decisions must be individualized, considering clinical evidence, patient preferences, comorbidities, tolerability, and financial factors for optimal outcomes.